Tina Jakob et al.
The Cochrane database of systematic reviews, 12, CD013020-CD013020 (2020-12-04)
Different bone-modifying agents like bisphosphonates and receptor activator of nuclear factor-kappa B ligand (RANKL)-inhibitors are used as supportive treatment in men with prostate cancer and bone metastases to prevent skeletal-related events (SREs). SREs such as pathologic fractures, spinal cord compression